Enzo Biochem (NYSE:ENZ) Getting Somewhat Positive News Coverage, Study Finds
Media headlines about Enzo Biochem (NYSE:ENZ) have trended somewhat positive this week, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Enzo Biochem earned a news impact score of 0.18 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 46.1596236342229 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Nektar’s (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag (mrtopstep.com)
- Unusual Activity Spotted in Enzo Biochem Inc (ENZ) – Evergreen Caller (evergreencaller.com)
- Global Biomarkers Market is poised to reach USD 46.12 billion by 2020 – 180 pages report by Market Data Forecast (emailwire.com)
- Novo Nordisk (NVO) Beats on Q2 Earnings, Revenues Miss (baetrice.org)
- The Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss (nasdaq.com)
Shares of Enzo Biochem (NYSE ENZ) traded up 0.64% during mid-day trading on Friday, hitting $11.06. 136,663 shares of the stock were exchanged. Enzo Biochem has a 12-month low of $4.88 and a 12-month high of $12.04. The company has a market capitalization of $513.26 million, a PE ratio of 15.36 and a beta of 0.97. The firm has a 50-day moving average price of $11.28 and a 200 day moving average price of $8.94.
Several brokerages have recently issued reports on ENZ. BidaskClub cut shares of Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Zacks Investment Research raised shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Tuesday, June 20th.
TRADEMARK VIOLATION NOTICE: “Enzo Biochem (NYSE:ENZ) Getting Somewhat Positive News Coverage, Study Finds” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/13/enzo-biochem-nyseenz-getting-somewhat-positive-news-coverage-study-finds.html.
Enzo Biochem Company Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.